[go: up one dir, main page]

NO20090541L - Prodrug av cinnamidforbindelse - Google Patents

Prodrug av cinnamidforbindelse

Info

Publication number
NO20090541L
NO20090541L NO20090541A NO20090541A NO20090541L NO 20090541 L NO20090541 L NO 20090541L NO 20090541 A NO20090541 A NO 20090541A NO 20090541 A NO20090541 A NO 20090541A NO 20090541 L NO20090541 L NO 20090541L
Authority
NO
Norway
Prior art keywords
prodrug
cinnamide compound
formula
group
cinnamide
Prior art date
Application number
NO20090541A
Other languages
English (en)
Inventor
Teiji Kimura
Koki Kawano
Noritaka Kitazawa
Nobuaki Sato
Toshihiko Kaneko
Koichi Ito
Mamoru Takaishi
Ikuo Kushida
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20090541L publication Critical patent/NO20090541L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cultivation Of Plants (AREA)
  • Seasonings (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Beskrevet er et optimalt prodrug til en cinnamidforbindelsen representert ved formel (I). I formelen representerer Ra og Rrespektivt en Cl-6 alkylgnippe eller lignende; Xrepresenterer en metoksygmppe eller et fiuoratom; Y representerer en fosfonogmppe eller lignende; og A representerer et cyklisk laktamderivat.
NO20090541A 2006-07-28 2009-02-03 Prodrug av cinnamidforbindelse NO20090541L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82076106P 2006-07-28 2006-07-28
JP2006206007 2006-07-28
US86925906P 2006-12-08 2006-12-08
JP2006331274 2006-12-08
PCT/JP2007/064637 WO2008013213A1 (en) 2006-07-28 2007-07-26 Prodrug of cinnamide compound

Publications (1)

Publication Number Publication Date
NO20090541L true NO20090541L (no) 2009-02-03

Family

ID=38981524

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090541A NO20090541L (no) 2006-07-28 2009-02-03 Prodrug av cinnamidforbindelse

Country Status (25)

Country Link
US (1) US7737141B2 (no)
EP (1) EP2048143A4 (no)
JP (1) JPWO2008013213A1 (no)
KR (1) KR20090033910A (no)
AR (1) AR062095A1 (no)
AU (1) AU2007277729A1 (no)
CA (1) CA2658037A1 (no)
CO (1) CO6150153A2 (no)
CR (1) CR10499A (no)
EA (1) EA200970172A1 (no)
EC (1) ECSP099091A (no)
GE (1) GEP20115176B (no)
HN (1) HN2009000157A (no)
IL (1) IL196351A0 (no)
MA (1) MA30636B1 (no)
MX (1) MX2008015504A (no)
MY (1) MY144971A (no)
NO (1) NO20090541L (no)
NZ (1) NZ574102A (no)
PE (1) PE20080281A1 (no)
SA (1) SA07280403B1 (no)
SV (1) SV2009003157A (no)
TN (1) TN2009000024A1 (no)
TW (1) TW200821319A (no)
WO (1) WO2008013213A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
WO2006046575A1 (ja) * 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. シンナミド化合物の非晶質体
EP1953151A4 (en) * 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
AU2006316005A1 (en) * 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI386207B (zh) * 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
TWI378091B (en) * 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
PE20081791A1 (es) * 2007-02-28 2009-02-07 Eisai Randd Man Co Ltd Dos derivados ciclicos de oxomorfolina
US20080306272A1 (en) * 2007-05-16 2008-12-11 Eisai R&D Management Co., Ltd. One-pot methods for preparing cinnamide derivatives
PE20090674A1 (es) * 2007-08-31 2009-06-19 Eisai Randd Man Co Ltd Compuestos multiciclicos
US7935815B2 (en) * 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
CA2710477A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
CN101910142B (zh) 2008-01-11 2013-07-10 弗·哈夫曼-拉罗切有限公司 β-淀粉状蛋白的调节剂
JPWO2009096349A1 (ja) * 2008-01-28 2011-05-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 結晶性のシンナミド化合物またはその塩
BRPI0907577A2 (pt) 2008-02-22 2015-07-21 Hoffmann La Roche Moduladores para amiloide beta
MX2011003246A (es) 2008-10-09 2011-04-21 Hoffmann La Roche Moduladores de beta amiloide.
MX2011004954A (es) 2008-11-10 2011-05-30 Hoffmann La Roche Moduladores heterociclicos de gamma-secretasa.
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
BR112013000050B1 (pt) * 2010-07-02 2021-10-19 Bio-Pharm Solutions Co., Ltd Compostos de carbamato de fenila e composição farmacêutica
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
BR112013013028B1 (pt) 2011-01-13 2021-02-09 Bio-Pharm Solutions Co., Ltd processo para a preparação de derivados de carbamato de fenila e composto
US8901066B2 (en) 2011-06-15 2014-12-02 Basf Se Branched polyesters with sulfonate groups
WO2012171998A1 (de) 2011-06-15 2012-12-20 Basf Se Verzweigte polyester mit sulfonatgruppen
KR101880584B1 (ko) * 2011-12-27 2018-07-20 (주)바이오팜솔루션즈 페닐 카바메이트 화합물의 간질의 예방 또는 치료 용도
KR101717871B1 (ko) * 2013-03-12 2017-03-20 (주)바이오팜솔루션즈 페닐카바메이트 화합물 및 이를 포함하는 기억 손실-관련 질환의 예방 또는 치료용 조성물
EP2968210B1 (en) 2013-03-12 2024-09-11 Bio-Pharm Solutions Co., Ltd. Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
HUE058802T2 (hu) * 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
CN110143935B (zh) * 2019-06-03 2022-09-30 华侨大学 一种2，5-二取代呋喃衍生物的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2061432T3 (es) 1985-10-09 1994-12-16 Shell Int Research Nuevas amidas de acido acrilico.
DE3541716A1 (de) 1985-11-26 1987-05-27 Celamerck Gmbh & Co Kg Neue acrylsaeureamide
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
DE69126251T2 (de) 1990-02-08 1997-09-25 Eisai Co Ltd Benzensulfonamidderivat
JPH05194517A (ja) 1992-01-16 1993-08-03 Tanabe Seiyaku Co Ltd ６−メルカプトプリン誘導体及びその製法
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
AU3577995A (en) 1994-10-04 1996-04-26 Fujisawa Pharmaceutical Co., Ltd. Urea derivatives and their use as acat-inhibitors
JPH08283219A (ja) 1995-04-07 1996-10-29 Eisai Co Ltd アラルキルアミノアルキルアミド誘導体
TR199802282T2 (xx) 1996-05-10 1999-03-22 Icos Corporation Karbolin t�revleri.
RU2202540C2 (ru) 1996-07-22 2003-04-20 Монсанто Компани Тиолсульфонамидные ингибиторы металлопротеазы
WO1998024785A1 (en) 1996-12-02 1998-06-11 Fujisawa Pharmaceutical Co., Ltd. Indole-urea derivatives with 5-ht antagonist properties
JP3108997B2 (ja) 1997-03-31 2000-11-13 武田薬品工業株式会社 アゾール化合物、その製造法および用途
WO1998043970A1 (en) 1997-03-31 1998-10-08 Takeda Chemical Industries, Ltd. Azole compounds, their production and their use
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
US6235728B1 (en) 1999-02-19 2001-05-22 Bristol-Myers Squibb Company Water-soluble prodrugs of azole compounds
NZ514453A (en) 1999-02-26 2003-04-29 Merck & Co Inc Novel sulfonamide compounds and uses thereof
AU2899400A (en) 1999-03-04 2000-09-21 Nortran Pharmaceuticals Inc. Aminocycloalkyl cinnamide compounds for arrhythmia and as analgesics and anesthetics
EP1264820A4 (en) 2000-03-14 2004-09-15 Fujisawa Pharmaceutical Co amide compounds
US20010051642A1 (en) 2000-04-17 2001-12-13 Kyunghye Ahn Method for treating Alzheimer's disease
AU2001254555A1 (en) 2000-04-24 2001-11-07 Merck Frosst Canada & Co Method of treatment using phenyl and biaryl derivatives as prostaglandin E inhibitors and compounds useful therefore
ATE288898T1 (de) 2000-12-04 2005-02-15 Hoffmann La Roche Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
GB0108770D0 (en) 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
EP1463714A4 (en) 2001-12-10 2005-10-19 Amgen Inc VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS
CN1289469C (zh) 2001-12-20 2006-12-13 布里斯托尔-迈尔斯斯奎布公司 α－(N－磺酰氨基)乙酰胺衍生物作为β－淀粉样蛋白抑制剂
JP2003206280A (ja) 2001-12-28 2003-07-22 Takeda Chem Ind Ltd ビアリール化合物およびその用途
DE10211101A1 (de) 2002-03-14 2003-09-25 Basf Ag Katalysatoren und Verfahren zur Herstellung von Aminen
GB0207436D0 (en) 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
WO2003099284A1 (en) 2002-05-22 2003-12-04 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
DK1511710T3 (en) 2002-05-31 2014-02-24 Proteotech Inc RELATIONSHIPS, PREPARATIONS AND METHODS FOR TREATING AMYLOID DISEASES AND SYNUCLEINOPATHES, SUCH AS ALZHEIMER'S DISEASE, TYPE 2-DIABETES AND PARKINSON'S DISEASE
KR20050025345A (ko) 2002-07-12 2005-03-14 아벤티스 파마 도이칠란트 게엠베하 헤테로사이클릭으로 치환된 벤조일우레아, 이들의제조방법 및 약제로서 이의 용도
US6900354B2 (en) 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
CN1747936A (zh) 2003-02-12 2006-03-15 特兰斯泰克制药公司 作为治疗试剂的取代吡咯衍生物
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
EP1663204B1 (en) 2003-08-29 2014-05-07 Exelixis, Inc. C-kit modulators and methods of use
JP4698604B2 (ja) 2003-12-22 2011-06-08 ファイザー・インク バソプレシン・アンタゴニストとしてのトリアゾール誘導体
US20050187277A1 (en) 2004-02-12 2005-08-25 Mjalli Adnan M. Substituted azole derivatives, compositions, and methods of use
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
WO2006046575A1 (ja) 2004-10-26 2006-05-04 Eisai R & D Management Co., Ltd. シンナミド化合物の非晶質体
US20060241038A1 (en) 2005-04-20 2006-10-26 Eisai Co., Ltd. Therapeutic agent for Abeta related disorders
WO2007034282A2 (en) 2005-09-19 2007-03-29 Pfizer Products Inc. Diaryl-imidazole compounds condensed with a heterocycle as c3a receptor antagonists
EP1953151A4 (en) 2005-11-18 2010-06-02 Eisai R&D Man Co Ltd SALTS FROM A CYNNAMIDE COMPOUND OR SOLVATE THEREOF
AU2006316005A1 (en) 2005-11-18 2007-05-24 Eisai R & D Management Co., Ltd. Process for production of cinnamamide derivative
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI386207B (zh) 2005-11-24 2013-02-21 Eisai R&D Man Co Ltd 味啉類型之肉桂醯胺化合物
US20070117839A1 (en) 2005-11-24 2007-05-24 Eisai R&D Management Co., Ltd. Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AU2007223158B2 (en) 2006-03-09 2012-04-12 Eisai R & D Management Co., Ltd. Polycyclic cinnamide derivative
SA07280403B1 (ar) 2006-07-28 2010-12-01 إيساي أر أند دي منجمنت كو. ليمتد ملح رباعي لمركب سيناميد
WO2008097538A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
US8357682B2 (en) 2007-05-07 2013-01-22 Zhaoning Zhu Gamma secretase modulators
MX2009012163A (es) 2007-05-11 2009-12-01 Hoffmann La Roche Hetarilanilinas como moduladores para beta-amiloide.
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
CA2695543A1 (en) 2007-08-06 2009-02-12 Schering Corporation Gamma secretase modulators

Also Published As

Publication number Publication date
SV2009003157A (es) 2010-01-12
HN2009000157A (es) 2011-01-24
WO2008013213A1 (en) 2008-01-31
MX2008015504A (es) 2008-12-18
CA2658037A1 (en) 2008-01-31
AR062095A1 (es) 2008-10-15
CO6150153A2 (es) 2010-04-20
SA07280403B1 (ar) 2010-12-01
KR20090033910A (ko) 2009-04-06
AU2007277729A1 (en) 2008-01-31
JPWO2008013213A1 (ja) 2009-12-17
TW200821319A (en) 2008-05-16
GEP20115176B (en) 2011-03-10
US20090048213A1 (en) 2009-02-19
US7737141B2 (en) 2010-06-15
EP2048143A4 (en) 2010-11-03
NZ574102A (en) 2010-10-29
EP2048143A1 (en) 2009-04-15
ECSP099091A (es) 2009-02-27
MY144971A (en) 2011-11-30
IL196351A0 (en) 2009-09-22
EA200970172A1 (ru) 2009-08-28
TN2009000024A1 (en) 2010-08-19
PE20080281A1 (es) 2008-05-05
MA30636B1 (fr) 2009-08-03
CR10499A (es) 2009-03-20

Similar Documents

Publication Publication Date Title
NO20090541L (no) Prodrug av cinnamidforbindelse
NO20070368L (no) Virale polymeraseinhibitorer
NO20084583L (no) Makrosykliske kinase-inhibitorer
EA200801381A1 (ru) Производные пиримидина
NO20065578L (no) Substituerte metylaryl eller heteroarylamidforbindelser
NO20065573L (no) Orto-substituerte aryl eller heteroarylamidforbindelser
DE602006019788D1 (de) Oximester-Fotoinitiatoren
NO20083390L (no) Piperaziner og piperidiner som mGluR5-forsterkere
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
WO2008108380A3 (en) Pyrrole compounds
WO2006133147A3 (en) Organic compounds
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
NZ592497A (en) Derivatives of 1-amino-2-cyclobutylethylboronic acid
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
RS54047B1 (en) PROCEDURE FOR OBTAINING 4-OXOCHINOLINE COMPOUNDS
WO2009054439A1 (ja) Pai-1産生抑制剤
WO2008126804A1 (ja) レジスト下層膜形成組成物
NO20075904L (no) Benzimidazolforbindelser
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20071012L (no) Fremgangsmate for fremstilling av D-erytro-2,2-difluor-2-deoksy-1-oksoribosederivat
ATE501103T1 (de) Organische verbindungen
MY146663A (en) Organic sulfur compound and its use for controlling harmful arthropod
EA200801365A1 (ru) Замещенные 5-фенил-3,6-дигидро-2-оксо-6h-1,3,4-тиадиазины

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application